Ötiroid nodüler guatra yaklaşım

ÜÇLER, RIFKI

Ötiroid nodüler guatra yaklaşım

Rıfkı ÜÇLER (Yıldırım Beyazıt Üniversitesi, Atatürk Eğitim ve Araştırma Hastanesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Hastalıkları, Ankara, Türkiye)

Van Tıp Dergisi

0 0

Yıl: 2014 Cilt: 21 Sayı: 2 Sayfa Aralığı: 123 - 128 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Ötiroid nodüler guatra yaklaşım

Öz:

Tiroid nodülü, tiroid bezinde parankimden farklı görünümde olarak ay ırt edilen bir lezyondur. Ülkemiz içinen önemli etyolojik faktör iyot eksiklidir ancak hem genetik hem de çevresel diğ er faktörlerin nodüler guatroluş umunda rol oynayabilmektedir. Klinikte kendini, boyunda rahats ızlık hissi, inspiratuar stridor, disfajive bo ğ ulma hissi, ses kıs ıklığ ı, artm ış tiroid hormon salınım ı ve tirotoksikoz gibi belirtilerle gösterebilirancak ço ğ u hasta asemptomatiktir. Malign olmas ı muhtemel nodülleri tanımak için, detaylı bir klinik öyküve dikkatli bir fizik muayene; laboratuar testleri, görüntüleme yöntemleri ve en önemlisi ince iğ neaspirasyon biyopsisi (İİ AB) ile desteklenmelidir. Tedavide; uygun hastalarda L-T 4 supresyon tedavisiverilebilir. Ciddi bas ı semptomlar ı veya malignite ş üphesi olan hastalarda cerrahi tedavi en uygunseçenektir.

Anahtar Kelime:

Konular: Cerrahi

The management of Euthyroid nodular goiter

Öz:

Thyroid nodule is a lesion which has a differentappearance from the rest of the thyroid tissue. In ourcountry the most important etiological factor isiodine deficiency but both genetic and otherenvironmental factors may play roles in thedevelopment of nodular goiter. The patients mayı present with compressive symptoms such as dyspnea,dysphagia and hoarseness and symptoms associatedwith thyrotoxicosis but most thyroid nodules areasymptomatic. To reveal malignant nodules a detailedanamnesis and physical examination should besupported by laboratory, imaging and mostimportantly fine needle aspiration biopsy. L-T4suppression treatment may be performed in somecases. Severe compressive symptoms or suspicion ofmalignancy necessiate surgical treatment.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Williams textbook of endocrinology, 12th edition, Sounders Company 2011, p. 327-329, 440-461.
2. Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules. Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 1968; 69(3):537-540.
3. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf) 1977; 7(6):481- 493.
4. Mortensen JD, Woolner LB, Bennett WA. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 1955; 15(10):1270-1280.
5. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med 1997; 126(3):226-231.
6. Hegedüs L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003; 24(1):102-132.
7. Krohn K, Führer D, Bayer Y, Eszlinger M, Brauer V, Neumann S, et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocr Rev 2005; 26(4):504-524.
8. Abs R, Stevenaert A, Beckers A. Autonomously functioning thyroid nodules in a patient with a thyrotropin-secreting pituitary adenoma: possible cause-effect relationship. Eur J Endocrinol 1994; 131(4):355-358.
9. Salvi M, Fukazawa H, Bernard N, Hiromatsu Y, How J, Wall JR. Role of autoantibodies in the pathogenesis and association of endocrine autoimmune disorders. Endocr Rev 1988; 9(4):450-466.
10. Foley TP Jr. Goiter in adolescents. Endocrinol Metab Clin North Am 1993; 22(3):593-606.
11. Glinoer D. The regulation of thyroid function during normal pregnancy: importance of the iodine nutrition status. Best Pract Res Clin Endocrinol Metab 2004; 18(2):133-152.
12. Alexander EK, Hurwitz S, Heering JP, Benson CB, Frates MC, Doubilet PM, et al. Natural history of benign solid and cystic thyroid nodules. Ann Intern Med 2003; 138(4):315-318.
13. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19(11):1167-1214.
14. Frates MC, Benson CB, Charboneau JW, Cibas ES, Clark OH, Coleman BG, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement. Radiology 2005; 237(3):794-800.
15. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002; 87(5):1941-1946.
16. Biondi B, Palmieri EA, Filetti S, Lombardi G, Fazio S. Mortality in elderly patients with subclinical hyperthyroidism. Lancet 2002; 359(9308):799-800.
17. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 2006; 91(11):4295-4301.
18. Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008; 93(3):809-814.
19. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab 2004; 89(1):163-168.
20. Costante G, Durante C, Francis Z, Schlumberger M, Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab 2009; 5(1):35-44.
21. Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer 2005; 5(5):367-375.
22. Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, et al. Medullary thyroid cancer: management guidelines of the American thyroid. Thyroid 2009; 19(6):565-612.
23. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid cancer of the follicular epithelium. Eur J Endocrinol 2006; 154(6):787-803.
24. Reading CC, Charboneau JW, Hay ID, Sebo TJ. Sonography of thyroid nodules: a "classic pattern" diagnostic approach. Ultrasound Q 2005; 21(3):157-165.
25. Zingrillo M, Torlontano M, Chiarella R, Ghiggi MR, Nirchio V, Bisceglia M, et al. Percutaneous ethanol injection may be a definitive treatment for symptomatic thyroid cystic nodules not treatable by surgery: five-year follow-up study. Thyroid 1999; 9(8):763-767.
26. Rago T, Vitti P. Role of thyroid ultrasound in the diagnostic evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008; 22(6):913-928.
27. Hamburger JI. Diagnosis of thyroid nodules by fine needle biopsy: use and abuse. J Clin Endocrinol Metab 1994; 79(2):335-339.
28. Gharib H. Changing concepts in the diagnosis and management of thyroid nodules. Endocrinol Metab Clin North Am 1997; 26(4):777-800.
29. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol 2008; 36(6):425-437.
30. Castro MR, Caraballo PJ, Morris JC. Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab 2002; 87(9):4154-4159.
31. Wémeau JL, Caron P, Schvartz C, Schlienger JL, Orgiazzi J, Cousty C, et al. Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double- blind, placebo-controlled trial by the French Thyroid Research Group. J Clin Endocrinol Metab 2002; 87(11):4928-4934.
32. Berghout A, Wiersinga WM, Drexhage HA, van Trotsenburg P, Smits NJ, van der Gaag RD, et al. The long-term outcome of thyroidectomy for sporadic non-toxic goitre. Clin Endocrinol (Oxf) 1989; 31(2):193-199.
33. Agerbaek H, Pilegaard HK, Watt-Boolsen S, Spangsberg N, Madsen MR, Laursen CN, et al. Complications of 2,028 operations for benign thyroid disease. Quantitative significance of various risk factors. Ugeskr Laeger 1988; 150(9):533-536.
34. Papini E, Guglielmi R, Bizzarri G, Pacella CM. Ultrasound-guided laser thermal ablation for treatment of benign thyroid nodules. Endocr Pract 2004; 10(3):276-283.

APA	ÜÇLER R (2014). Ötiroid nodüler guatra yaklaşım. , 123 - 128.
Chicago	ÜÇLER RIFKI Ötiroid nodüler guatra yaklaşım. (2014): 123 - 128.
MLA	ÜÇLER RIFKI Ötiroid nodüler guatra yaklaşım. , 2014, ss.123 - 128.
AMA	ÜÇLER R Ötiroid nodüler guatra yaklaşım. . 2014; 123 - 128.
Vancouver	ÜÇLER R Ötiroid nodüler guatra yaklaşım. . 2014; 123 - 128.
IEEE	ÜÇLER R "Ötiroid nodüler guatra yaklaşım." , ss.123 - 128, 2014.
ISNAD	ÜÇLER, RIFKI. "Ötiroid nodüler guatra yaklaşım". (2014), 123-128.

APA	ÜÇLER R (2014). Ötiroid nodüler guatra yaklaşım. Van Tıp Dergisi, 21(2), 123 - 128.
Chicago	ÜÇLER RIFKI Ötiroid nodüler guatra yaklaşım. Van Tıp Dergisi 21, no.2 (2014): 123 - 128.
MLA	ÜÇLER RIFKI Ötiroid nodüler guatra yaklaşım. Van Tıp Dergisi, vol.21, no.2, 2014, ss.123 - 128.
AMA	ÜÇLER R Ötiroid nodüler guatra yaklaşım. Van Tıp Dergisi. 2014; 21(2): 123 - 128.
Vancouver	ÜÇLER R Ötiroid nodüler guatra yaklaşım. Van Tıp Dergisi. 2014; 21(2): 123 - 128.
IEEE	ÜÇLER R "Ötiroid nodüler guatra yaklaşım." Van Tıp Dergisi, 21, ss.123 - 128, 2014.
ISNAD	ÜÇLER, RIFKI. "Ötiroid nodüler guatra yaklaşım". Van Tıp Dergisi 21/2 (2014), 123-128.